Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with…
Central Nervous System
-
-
Biohaven secures $600m financing as it awaits FDA prodrug decision
Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with non-dilutive capital…
-
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a…
-
FDA approves Neurelis’ nasal spray for seizures
The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute…
-
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease.…
-
Cingulate secures $3m to advance once-daily anxiety treatment
US biopharmaceutical company Cingulate has announced the receipt of a $3m grant from a private foundation to expedite the development…
-
ABL Bio and GSK link on neurodegenerative conditions
ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through…
-
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for…
-
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs)…
-
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
